These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 4044586)
21. A new 'solid phase' procedure to synthesize immunotoxins (antibody-ribosome inactivating protein conjugates). Dosio F; Brusa P; Delprino L; Ceruti M; Grosa G; Cattel L; Bolognesi A; Barbieri L Farmaco; 1993 Jan; 48(1):105-15. PubMed ID: 8457275 [TBL] [Abstract][Full Text] [Related]
22. A new approach in the synthesis of immunotoxins: ribosome inactivating protein noncovalently bound to monoclonal antibody. Dosio F; Brusa P; Delprino L; Grosa G; Ceruti M; Cattel L J Pharm Sci; 1994 Feb; 83(2):206-11. PubMed ID: 8169790 [TBL] [Abstract][Full Text] [Related]
23. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin. Rosenblum MG; Marks JW; Cheung LH Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583 [TBL] [Abstract][Full Text] [Related]
24. Immunological and biological stability of immunotoxins in vivo as studied by the clearance of disulfide-linked pokeweed antiviral protein-antibody conjugates from blood. Ramakrishnan S; Houston LL Cancer Res; 1985 May; 45(5):2031-6. PubMed ID: 3986759 [TBL] [Abstract][Full Text] [Related]
25. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. V. Evidence that humoral immune response to monoclonal antibodies and immunotoxin conjugates abrogates their cytotoxic activity. Reimann KA; Turner S; Lambert JM; Reed MH; Schlossman SF; Letvin NL Transplantation; 1989 Dec; 48(6):906-12. PubMed ID: 2574507 [TBL] [Abstract][Full Text] [Related]
26. Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies. Sforzini S; Bolognesi A; Meazza R; Marciano S; Tazzari PL; Stein H; Stirpe F; Ferrini S J Hematother; 1995 Oct; 4(5):429-32. PubMed ID: 8581380 [TBL] [Abstract][Full Text] [Related]
27. Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins. Bolognesi A; Tazzari PL; Olivieri F; Polito L; Falini B; Stirpe F Int J Cancer; 1996 Nov; 68(3):349-55. PubMed ID: 8903477 [TBL] [Abstract][Full Text] [Related]
28. Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule. Myers DE; Yanishevski Y; Masson E; Irvin JD; Evans WE; Uckun FM Leuk Lymphoma; 1995 Jun; 18(1-2):93-102. PubMed ID: 8580835 [TBL] [Abstract][Full Text] [Related]
29. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688 [TBL] [Abstract][Full Text] [Related]
30. The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin. Scott CF; Goldmacher VS; Lambert JM; Chari RV; Bolender S; Gauthier MN; Blättler WA Cancer Immunol Immunother; 1987; 25(1):31-40. PubMed ID: 3496157 [TBL] [Abstract][Full Text] [Related]
31. Chemical construction of immunotoxins. Ghetie V; Vitetta ES Mol Biotechnol; 2001 Jul; 18(3):251-68. PubMed ID: 11503519 [TBL] [Abstract][Full Text] [Related]
32. Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin. Stirpe F; Wawrzynczak EJ; Brown AN; Knyba RE; Watson GJ; Barbieri L; Thorpe PE Br J Cancer; 1988 Nov; 58(5):558-61. PubMed ID: 3265330 [TBL] [Abstract][Full Text] [Related]
34. Large scale manufacturing of TXU(anti-CD7)-pokeweed antiviral protein (PAP) immunoconjugate for clinical trials. Myers DE; Jun X; Clementson D; Donelson R; Sicheneder A; Hoffman N; Bell K; Sarquis M; Langlie MC; Turner N; Uckun FM Leuk Lymphoma; 1997 Oct; 27(3-4):275-302. PubMed ID: 9402326 [TBL] [Abstract][Full Text] [Related]
35. Toxicity of, and histological lesions caused by, ribosome-inactivating proteins, their IgG-conjugates, and their homopolymers. Battelli MG; Barbieri L; Stirpe F APMIS; 1990 Jul; 98(7):585-93. PubMed ID: 2397111 [TBL] [Abstract][Full Text] [Related]
36. Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line. Battelli MG; Polito L; Bolognesi A; Lafleur L; Fradet Y; Stirpe F Int J Cancer; 1996 Feb; 65(4):485-90. PubMed ID: 8621232 [TBL] [Abstract][Full Text] [Related]
37. In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. Bolognesi A; Polito L; Tazzari PL; Lemoli RM; Lubelli C; Fogli M; Boon L; de Boer M; Stirpe F Br J Haematol; 2000 Aug; 110(2):351-61. PubMed ID: 10971392 [TBL] [Abstract][Full Text] [Related]
38. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. IV. Cytotoxic effect of an anti-T11-gelonin immunotoxin. Reimann KA; Goldmacher VS; Lambert JM; Chalifoux LV; Cook SB; Schlossman SF; Letvin NL J Clin Invest; 1988 Jul; 82(1):129-38. PubMed ID: 2899092 [TBL] [Abstract][Full Text] [Related]
39. Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates. Sivam G; Pearson JW; Bohn W; Oldham RK; Sadoff JC; Morgan AC Cancer Res; 1987 Jun; 47(12):3169-73. PubMed ID: 3495329 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+ cells by monoclonal antibodies. Zarling JM; Moran PA; Haffar O; Sias J; Richman DD; Spina CA; Myers DE; Kuebelbeck V; Ledbetter JA; Uckun FM Nature; 1990 Sep; 347(6288):92-5. PubMed ID: 1975641 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]